-transparent.png){kind=logo}
The Southwest Oncology Group studied the response rate and toxicity of didemnin B (3.47 mg/m2 i.v. q 28 days) in patients with advanced renal cell carcinoma. There were no responses in 22 response evaluable patients. Toxicity was significant with 10 patients having grade 3 or 4 toxicity. Toxicity seen included nausea and vomiting, exacerbation of coronary artery disease, hyperglycemia, anorexia, diarrhea and hepatitis. Didemnin B was toxic but inactive in patients with renal cell treated at this dose.
Related Publications
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
April 1992,
Investigational new drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
January 1995,
Investigational new drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
January 1998,
Investigational new drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
April 1994,
Anti-cancer drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
December 1987,
Cancer treatment reports,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
January 1994,
Cancer investigation,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
February 1990,
Investigational new drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
August 1979,
Cancer treatment reports,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
February 1990,
Investigational new drugs,
S A Taylor, and
P Goodman, and
E D Crawford, and
W J Stuckey, and
R L Stephens, and
E R Gaynor
July 1976,
Cancer,
